Product Name: Nitrotyrosine
Product Number: AB-CN007-1
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Nitrotyrosine residues in proteins
Target Alias: Nitro tyrosine; 3-Nitrotyrosine
Product Type Specific: Generic nitrotyrosine-specific pan-specific antibody
Antibody Code: CN007-1
Antibody Target Type: Pan-specific
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG2a
Antibody Immunogen Source: Hybridoma line 39B6
Production Method: Protein G purified
Target Alias: Nitro tyrosine; 3-Nitrotyrosine
Product Type Specific: Generic nitrotyrosine-specific pan-specific antibody
Antibody Code: CN007-1
Antibody Target Type: Pan-specific
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG2a
Antibody Immunogen Source: Hybridoma line 39B6
Production Method: Protein G purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:1400); optimal dilutions for assays should be determined by the user.
Antibody Potency: Medium potency. Recognizes 3-nitrotyrosine moieties.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:1400); optimal dilutions for assays should be determined by the user.
Antibody Potency: Medium potency. Recognizes 3-nitrotyrosine moieties.
Antibody Species Reactivity: Human | Mouse | Rat | Dog
Antibody Positive Control: 0.7 µg/ml of SMC-154 was sufficient for detection of 5 µg SIN-1 treated BSA by Western Blot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Very high
Antibody Cross Reactivity: No detectable cross-reactivity with non-nitrated tyrosine.
Antibody Positive Control: 0.7 µg/ml of SMC-154 was sufficient for detection of 5 µg SIN-1 treated BSA by Western Blot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Very high
Antibody Cross Reactivity: No detectable cross-reactivity with non-nitrated tyrosine.
Scientific Background: Protein tyrosine nitration results in a post-translational modification that is increasingly receiving attention as an important component of nitric oxide signaling (2). While multiple nonenzymatic mechanisms are known to be capable of producing nitrated tyrosine residues, most tyrosine nitration events involve catalysis by metalloproteins such as myeloperoxidase, eosino-philperoxidase (3), myoglobin, the cytochrome P-450s, superoxide dismutase and prostacyclin synthase.
Nitrotyrosine may also serve as a biomarker for the effects of reactive nitrogen oxides, based on tyrosine residues becoming nitrated in proteins at sites of inflammation induced tissue injury (1). The presence of nitro tyrosine-containing proteins therefore has shown high correlation to disease states such as atherosclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (4).
References
[1] Girault I. et al. (2001). Free Radical Biology and Medicine, 31 (11): 1375-1387.
[2] Gow AJ, Farkouh CR, Munson DA, Posencheq MA, and Ischiropoulos H. (2004). Am J Physiol Lung Cell Mol Physiol. 287(2): L262-8.
[3] Takemoto K. et al (2007). Acta Med Okayama 61(1): 17-30.
[4] Reynolds MR. et al. (2006) J Nerosci. 26(42): 10636-45.
[5] Pfister H. et al. (2002) Vet Pathol. 39: 190-199.
[6] Khan J. et al. (1998) Biochem J. 330(2): 795-801.
[1] Girault I. et al. (2001). Free Radical Biology and Medicine, 31 (11): 1375-1387.
[2] Gow AJ, Farkouh CR, Munson DA, Posencheq MA, and Ischiropoulos H. (2004). Am J Physiol Lung Cell Mol Physiol. 287(2): L262-8.
[3] Takemoto K. et al (2007). Acta Med Okayama 61(1): 17-30.
[4] Reynolds MR. et al. (2006) J Nerosci. 26(42): 10636-45.
[5] Pfister H. et al. (2002) Vet Pathol. 39: 190-199.
[6] Khan J. et al. (1998) Biochem J. 330(2): 795-801.
© Kinexus Bioinformatics Corporation 2017